← Leaderboards
Doris A Taylor
Duke University
$6,306,380
Attributed
$10,630,205
Total exposure
6
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.8M · FY2005–19$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$10,630,205 · 6
By mechanism
R01$7,022,735 · 4
U01$3,362,970 · 1
R21$244,500 · 1
Top collaborators
- Angela Panoskaltsis-Mortari7 shared
- Daniel J. Garry3 shared
- Dan S Kaufman3 shared
- Michael Kyba3 shared
- Jonathan M. Slack3 shared
- Jianyi Zhang3 shared
Most similar at Duke University
Same institution · by research overlap
- Kenneth D Poss$25,540,868
- Tatiana Segura$14,175,920
- Gentzon Hall$793,932
- Kathryn R Nightingale$16,760,750
- Nenad Bursac$22,509,345
Others in their field
Top investigators on “Myocardial Infarction”
- Judith S Hochman · New York University School Of Medicine$121,330,744
- Paul M. Ridker · Brigham And Women'S Hospital$57,742,470
- Gervasio A Lamas · Mount Sinai Medical Center (Miami Beach)$57,397,502
- Pamela Susan Douglas · Duke University$51,876,470
- Julie E Buring · Brigham And Women'S Hospital$46,647,558
- Walter N Kernan · Yale University$42,197,025
Research focus
Myocardial InfarctionCell TransplantationMyocardiumMyoblastsCellsHeartHeart ContractionInduced Pluripotent Stem CellExtracellular MatrixStem CellsBone MarrowBlood VesselsProgenitorCuesLaboratory RabbitAutologousTissue /Cell CulturePropertyVascular Endothelial Growth FactorsImplantCharacteristicsInterestOrganClinic
Grant awards (25)
Using a Cardiac Microtissue System to Evaluate and Replicate Clinical Therapy Responses using Patient Cell-Derived Exosomes$244,500
R21 · FY2019 · HL · contact PI
Overcoming Barriers to Bioengineering 3-D Human Lung$710,953
R01 · FY2014 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$155,856
R01 · FY2014 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$30,183
R01 · FY2014 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$705,631
R01 · FY2013 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$701,107
R01 · FY2012 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$48,561
R01 · FY2012 · HL
Midwestern Progenitor Cell Consortium$1,120,620
U01 · FY2011 · HL
Overcoming Barriers to Bioengineering 3-D Human Lung$690,410
R01 · FY2011 · HL
Midwestern Progenitor Cell Consortium$1,109,850
U01 · FY2010 · HL
Midwestern Progenitor Cell Consortium$1,132,500
U01 · FY2009 · HL
Safety and Efficacy of Cellular Cardiomyoplasty$347,414
R01 · FY2007 · HL · contact PI
Safety and Efficacy of Cellular Cardiomyoplasty$360,631
R01 · FY2006 · HL · contact PI
Safety and Efficacy of Cellular Cardiomyoplasty$371,250
R01 · FY2005 · HL
Safety and Efficacy of Cellular Cardiomyoplasty$371,250
R01 · FY2004 · HL
AUGMENTING MYOCARDIAL REGENERATION THROUGH ANGIOGENESIS$223,203
R01 · FY2003 · HL
AUGMENTING MYOCARDIAL REGENERATION THROUGH ANGIOGENESIS$123,297
R01 · FY2003 · HL
AUGMENTING MYOCARDIAL REGENERATION THROUGH ANGIOGENESIS$346,500
R01 · FY2002 · HL
SAFETY AND EFFICACY OF CELLULAR CARDIOMYOPLASTY$327,640
R01 · FY2002 · HL
AUGMENTING MYOCARDIAL REGENERATION THROUGH ANGIOGENESIS$371,500
R01 · FY2001 · HL
SAFETY AND EFFICACY OF CELLULAR CARDIOMYOPLASTY$318,096
R01 · FY2001 · HL
DEVELOPING CELLULAR CARDIOMYOPLASTY FOR INJURED HEART$77,000
R01 · FY2001 · HL
AUGMENTING MYOCARDIAL REGENERATION THROUGH ANGIOGENESIS$325,623
R01 · FY2000 · HL
SAFETY AND EFFICACY OF CELLULAR CARDIOMYOPLASTY$308,830
R01 · FY2000 · HL
DEVELOPING CELLULAR CARDIOMYOPLASTY FOR INJURED HEART$107,800
R01 · FY2000 · HL